76345-09-0

Basic information

• Product Name: ethyl 2-(4-nitrobenzoyl)-3-dimethylaminopropenoate
• Synonyms: ethyl 2-(4-nitrobenzoyl)-3-dimethylaminopropenoate
• CAS NO: 76345-09-0
• Molecular Weight: 292.291
• Mol File: 76345-09-0.mol

Chemical Properties

• CAS DataBase Reference: ethyl 2-(4-nitrobenzoyl)-3-dimethylaminopropenoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-nitrobenzoyl)-3-dimethylaminopropenoate(76345-09-0)
• EPA Substance Registry System: ethyl 2-(4-nitrobenzoyl)-3-dimethylaminopropenoate(76345-09-0)

Safety Data

• Hazardous Substances Data: 76345-09-0(Hazardous Substances Data)

Upstream product

• 838-57-3 ethyl 4-nitrobenzoylacetate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 

Downstream Products

• 146379-76-2 2-(4-chlorophenyl)-4-(4-nitrophenyl)-5-pyrimidinecarboxylic acid 
• 103312-32-9 4-(4-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylic acid 

Relevant articles and documents

Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004

New heteroarylcarboxamide head groups substituted with two aromatic rings analogs of thieno[3,2-b]pyridine-based kinase inhibitor LCRF-0004 were designed and synthesized. Potent inhibitors of RON tyrosine kinase with various level of selectivity for c-Met RTK were obtained.

4-Substituted 1,5-diarylpyrazole, analogues of celecoxib: Synthesis and preliminary evaluation of biological properties

A number of 5-aryl-1-[4-(methylsulfonyl)-phenyl]-1H-pyrazoles and 4-(5-aryl-1H-pyrazol-1-yl)benzenesulfonamides 3, 4, 5, 6, analogues of the COX-2 selective inhibitor celecoxib (celebrex), were synthesized. In order to verify the effects on the biological properties of certain substituents put on position 4 of the pyrazole nucleus, some of these compounds were screened in vivo for their anti-inflammatory and analgesic activities. Moreover, sodium salts of carboxylic acids 4 were tested in vitro for their platelet anti-aggregating properties. The results of these preliminary biological assays showed that new derivatives are not endowed with improved anti-inflammatory and analgesic properties, in comparison with celecoxib. In addition, docking studies were carried out on the most significative compounds to evaluate their interaction mode at the active site of both COX-1 and COX-2. Some remarks about the SAR of this class of COX-inhibitors are drown out.

Studies on cerebral protective agents. II. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities.

In a search for new cerebral protective agents with anti-anoxic (AA) and anti-lipid peroxidation (ALP) activities, a series of 4-arylpyrimidines, bearing an amino moiety in the C-5 position of the pyrimidine nucleus, was synthesized and tested for AA and